Vertex To Acquire Crinetics For ~$10bn - What Investors Should Know

Vertex Pharmaceuticals Incorporated’s $10B Crinetics Pharmaceuticals, Inc. buy adds PALSONIFY & a Phase 3 CAH asset. Click ...

Vertex sees over $5 billion peak sales potential from Crinetics assets

Vertex Pharmaceuticals Incorporated VRTX on Monday agreed to acquire Crinetics Pharmaceuticals Inc. CRNX for $85 per share in ...
pharmaphorum

Vertex scores double win with non-opioid pain drug

Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.

A year after distressed buyout, what’s become of Somerville’s Bluebird Bio?

David Meek bought the company last year for the pharma industry equivalent of loose change. The company was on the brink of ...
BioSpace

Vertex’s Casgevy becomes first approved gene therapy for young kids with rare blood disorders

The FDA approved the expansion of Casgevy, which had previously been greenlit for patients 12 and up, into a younger pediatric population under the agency’s Commissioner’s National Priority Voucher ...

Vertex Pharmaceuticals: Povetacicept May Redefine Growth Narrative (Rating Upgrade)

R&D wins beyond cystic fibrosis, with the povetacicept FDA decision coming for IgA nephropathy. Click for this VRTX update.
YouTube on MSNOpinion

Finally understand completing the square

In this video, we provide essential "math help" by explaining the process of "completing the square" to convert "quadratic ...
Investopedia

Master SEC Form S-3: Filing Process, Benefits & Key Requirements

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...